RBC Capital Initiates Coverage On Ambrx Biopharma with Outperform Rating, Announces Price Target of $29
Portfolio Pulse from richadhand@benzinga.com
RBC Capital analyst Brian Abrahams has initiated coverage on Ambrx Biopharma (NASDAQ:AMAM) with an Outperform rating and a price target of $29.
July 31, 2023 | 11:20 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ambrx Biopharma has received an Outperform rating from RBC Capital, with a price target of $29.
The Outperform rating from RBC Capital indicates a positive outlook for Ambrx Biopharma. The price target of $29 suggests a potential upside from the current price. This could lead to increased investor interest and a potential increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100